Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Impax Laboratories (IPXL) PT Raised to $20 at Cowen Following Strong 2Q
August 9, 2017 1:54 PM EDTCowen raised its price target on Impax Laboratories (NASDAQ: IPXL) to $20.00 (from $12.00) while maintaining a Market Perform rating.
Impax reported 2Q results that were above expectations as total revenues of $202MM were $6MM above the Street's estimate. The better revenues and better... More
Impax Laboratories (IPXL) Tops Q2 EPS by 4c
August 9, 2017 7:08 AM EDTImpax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.18, $0.04 better than the analyst estimate of $0.14. Revenue for the quarter came in at $202.1 million versus the consensus estimate of $195.62 million.
GUIDANCE:
Impax Laboratories sees FY2017 EPS of $0.55-$0.70, versus the consensus of... More
